Evidence map›Paper›PMID 29578539›Full record

ArticleNature medicine2018

Targeting hepatic glutaminase activity to ameliorate hyperglycemia.

Russell A Miller, Yuji Shi, Wenyun Lu, David A Pirman, Aditi Jatkar, Matthew Blatnik, Hong Wu, César Cárdenas, Min Wan, J Kevin Foskett and 5 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Clinical and Metabolic Signatures ofKidney international reports · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer.Endocrinology and metabolism (Seoul, Korea) · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Russell A MillerInstitute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yuji ShiPfizer Internal Medicine Research Units, Cambridge, Massachusetts, USA.
Wenyun LuChemistry and Integrative Genomics, Princeton University, Princeton, New Jersey, USA.
David A PirmanPfizer Worldwide Research and Development, Groton, Connecticut, USA.
Aditi JatkarPfizer Internal Medicine Research Units, Cambridge, Massachusetts, USA.
Matthew BlatnikPfizer Worldwide Research and Development, Groton, Connecticut, USA.
Hong WuPfizer Worldwide Research and Development, Groton, Connecticut, USA.
César CárdenasAnatomy and Developmental Biology Program, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
Min WanPfizer Internal Medicine Research Units, Cambridge, Massachusetts, USA.
J Kevin FoskettDepartment of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-8854-0268
Junyoung O ParkChemistry and Integrative Genomics, Princeton University, Princeton, New Jersey, USA.ORCID 0000-0001-9869-8993
Yiyi ZhangTouchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
William L HollandTouchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-9950-1435
Joshua D RabinowitzChemistry and Integrative Genomics, Princeton University, Princeton, New Jersey, USA.
Morris J BirnbaumInstitute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-9972-8680
Pfizer (United States) · USPrinceton University · USThe University of Texas Southwestern Medical Center · USBuck Institute for Research on Aging · USUniversity of Pennsylvania · US

Funding

Liver-islet and intra-islet cross talk in alpha cell hyperplasia and beta cell regenerationR01DK112826 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2017 to 2025
$3.4M
Sphingolipid-Mediated Dysregulation of Glucose and Energy Homeostasis in the CNSR01DK108833 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HOLLAND, WILLIAM L · 2016 to 2020
$1.8M
Revealing cancer metabolism via mass spectrometry and isotope tracersR50CA211437 · NCI · PRINCETON UNIVERSITY · PI Wenyun Lu · 2016 to 2026
$1.3M
NCI NIH HHS R50 CA211437NIDDK NIH HHS R01 DK108833NIDDK NIH HHS R01 DK112826
6 · The paper itself

Abstract

Glucagon levels increase under homeostatic, fasting conditions, promoting the release of glucose from the liver by accelerating the breakdown of glycogen (also known as glycogenolysis). Glucagon also enhances gluconeogenic flux, including from an increase in the hepatic consumption of amino acids. In type 2 diabetes, dysregulated glucagon signaling contributes to the elevated hepatic glucose output and fasting hyperglycemia that occur in this condition. Yet, the mechanism by which glucagon stimulates gluconeogenesis remains incompletely understood. Contrary to the prevailing belief that glucagon acts primarily on cytoplasmic and nuclear targets, we find glucagon-dependent stimulation of mitochondrial anaplerotic flux from glutamine that increases the contribution of this amino acid to the carbons of glucose generated during gluconeogenesis. This enhanced glucose production is dependent on protein kinase A (PKA) and is associated with glucagon-stimulated calcium release from the endoplasmic reticulum, activation of mitochondrial α-ketoglutarate dehydrogenase, and increased glutaminolysis. Mice with reduced levels of hepatic glutaminase 2 (GLS2), the enzyme that catalyzes the first step in glutamine metabolism, show lower glucagon-stimulated glutamine-to-glucose flux in vivo, and GLS2 knockout results in higher fasting plasma glucagon and glutamine levels with lower fasting blood glucose levels in insulin-resistant conditions. As found in genome-wide association studies (GWAS), human genetic variation in the region of GLS2 is associated with higher fasting plasma glucose; here we show in human cryopreserved primary hepatocytes in vitro that these natural gain-of-function missense mutations in GLS2 result in higher glutaminolysis and glucose production. These data emphasize the importance of gluconeogenesis from glutamine, particularly in pathological states of increased glucagon signaling, while suggesting a possible new therapeutic avenue to treat hyperglycemia.

Indexed as

AnimalsCells, CulturedCryopreservationGlucagonGlutaminaseGlutamineHepatocytesHumansHyperglycemiaKineticsLiverMetabolic Flux AnalysisMice, Inbred C57BLMice, KnockoutGlucagonGlutaminaseGlutamine

Identifiers

PMID29578539
PMCPMC6089616
OpenAlexW2790636498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.